BH4 Domain Peptides Derived From BCL-2/BCL-Xl as Novel Tools Against Acute Pancreatitis

Cell Death Discovery - United Kingdom
doi 10.1038/s41420-018-0054-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

BH4 Domain of BCL-2 as a Novel Target for Cancer Therapy

Drug Discovery Today
Drug DiscoveryPharmacology
2016English

Mechanism of BCL-2 and BCL-Xl Inhibition of NLRP1 Inflammasome: Loop Domain-Dependent Suppression of ATP Binding and Oligomerization

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

Combined Inhibition of Notch Signaling and BCL-2/BCL-xL Results in Synergistic Antimyeloma Effect

Molecular Cancer Therapeutics
Cancer ResearchOncology
2010English

The BCL-2 Proteins Noxa and BCL-xL Co-Ordinately Regulate Oxidative Stress-Induced Apoptosis

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2012English

BCL-xL in Neuroprotection and Plasticity

Frontiers in Physiology
Physiology
2014English

Expression Profile of BCL-2, BCL-XL, and McL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Structure-Based Design of Potent BCL-2/BCL-xL Inhibitors With Strong in Vivo Antitumor Activity

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2012English

NH2-terminal BH4 Domain of BCL-2 Is Functional for Heterodimerization With Bax and Inhibition of Apoptosis

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
1999English

Novel Small-Molecule Inhibitors of BCL-Xl to Treat Lung Cancer

Cancer Research
Cancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy